ST Germain D J Co. Inc. Raises Stake in Amgen Inc. (NASDAQ:AMGN)

ST Germain D J Co. Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,515 shares of the medical research company’s stock after acquiring an additional 167 shares during the period. Amgen comprises approximately 1.2% of ST Germain D J Co. Inc.’s portfolio, making the stock its 18th biggest holding. ST Germain D J Co. Inc.’s holdings in Amgen were worth $25,707,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AMGN. Vanguard Group Inc. boosted its position in Amgen by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company’s stock valued at $13,741,409,000 after buying an additional 339,522 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock valued at $3,441,909,000 after acquiring an additional 2,672,975 shares during the period. Geode Capital Management LLC grew its position in Amgen by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company’s stock worth $3,245,881,000 after acquiring an additional 352,143 shares during the last quarter. Capital International Investors increased its stake in Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after purchasing an additional 3,495,503 shares during the period. Finally, Capital World Investors increased its stake in Amgen by 1,292.0% in the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after purchasing an additional 6,029,058 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on AMGN. Piper Sandler decreased their target price on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research note on Friday, May 16th. UBS Group restated a “neutral” rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 18th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. Finally, Cantor Fitzgerald started coverage on Amgen in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $305.00 price objective for the company. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $309.22.

Amgen Stock Performance

Shares of AMGN stock opened at $288.47 on Tuesday. The company has a market capitalization of $155.11 billion, a price-to-earnings ratio of 38.21, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company’s 50-day moving average is $283.12 and its 200 day moving average is $285.27.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same period in the prior year, the firm posted $3.96 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.